BRIEF-Horizon Therapeutics Says Received European Commission Approval Of Uplizna
* HORIZON THERAPEUTICS PLC RECEIVES EUROPEAN COMMISSION (EC) APPROVAL OF UPLIZNA® (INEBILIZUMAB) FOR THE TREATMENT OF ADULTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)
* HORIZON THERAPEUTICS (HZNP) - EC APPROVAL SUPPORTED BY RESULTS FROM N-MOMEMTUM, SHOWED 87.6% OF AQP4-IGG+ NMOSD PATIENTS ON UPLIZNA WERE ATTACK FREE FOR 28 WEEKS Source text for Eikon: Further company coverage: